AstraZeneca Patient Assistance Programs Provided Hundreds of Millions of Dollars of Support in 2015 to Help Patients Afford Medicines

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca today announced that its AZ&Me™ Prescription Savings
Programs provided more than $617 million in savings on medicines to
patients in the United States in 2015. The programs supported nearly
322,500 patients last year.

“As the healthcare market continues to change, patients sometimes need
support in paying for their prescription medicines,” said Diane
Sullivan, Vice President, Market Access and Patient Strategies. “We are
proud of our long-standing commitment to making great medicines – and
helping patients access them.”

Since 2010, AstraZeneca has provided more than $5.5 billion in savings
to patients in its savings programs. The programs are designed to help
qualifying people without insurance, those enrolled in Medicare Part D,
those who receive their medications through participating healthcare
facilities and those who recently faced a financial challenge – such as
loss of a job.

• Individuals without Prescription Drug Coverage: AstraZeneca
  provides free medicines to qualifying individuals with an annual
  income at or below $35,000 and families of four with an annual
  household income at or below $70,000. Certain specialty and oncology
  medicines are provided free to qualifying individuals with an annual
  household income up to $100,000 regardless of family size.
• Part D Beneficiaries: AstraZeneca provides free medicines to
  qualifying Medicare Part D beneficiaries with an annual income at or
  below $35,000 and couples with an annual household income at or below
  $48,000.
• Healthcare Facilities: AstraZeneca provides free medicines to
  qualifying non-profit organizations, such as disproportionate share
  hospitals, community health centers and community free clinics. This
  program helps provide medicines to qualifying patients at the time and
  place of treatment.

AstraZeneca first launched its prescription savings program more than 35
years ago, helping millions of patients afford the medicines they need.
The company also participates in multi-manufacturer programs like the
Partnership for Prescription Assistance and support other
organizations with the same goal—increasing access to medicines as
well as healthcare.

NOTES TO EDITORS

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business
that focuses on the discovery, development and commercialization of
prescription medicines, primarily for the treatment of diseases in three
main therapy areas – respiratory, inflammation, autoimmune disease
(RIA), cardiovascular and metabolic disease (CVMD) and oncology – as
well as in infection and neuroscience. AstraZeneca operates in over 100
countries and its innovative medicines are used by millions of patients
worldwide. For more information please www.astrazeneca-us.com.

For more information about AstraZeneca in the United States, or our
AZ&Me Prescription Savings Programs, please visit www.astrazeneca-us.com
or call 1-800-AZandMe (292-6363).

AZ&Me is a trademark of the AstraZeneca group of companies. ©2015
AstraZeneca. All rights reserved.

Contacts

AstraZeneca
Media Inquiries
Michele Meixell, +1
302-885-2677
or
Abigail Bozarth, +1 302-885-2677